The drug, ANX-201, combined at fixed ratios with nucleoside and nucleotide reverse transcriptase inhibitors (N(t)RTIs) including zidovudine, tenofovir, abacavir, lamivudine, emtricitabine and stavudine resulted in synergistic to additive inhibition of HIV-1 in cultured human cells using standard in vitro assays.
Furthermore, this synergistic activity suggests that the addition of ANX-201 to a drug regimen containing N(t)RTIs may have clinical advantages that include enhanced antiviral activity and the potential for reduced toxicity, the San Diego-based company said.
Evan Levine, Adventrx’s CEO, said: “These data suggest that ANX-201 in combination with N(t)RTIs has potential clinical advantages for HIV patients, including enhanced viral suppression and slowed progression of drug resistance. We are excited about these results and expect to initiate a clinical trial with ANX-201 as a component of multi-drug therapy for the treatment of HIV later this year.”